Log in

Relevant bibliographies by topics / Second-line therapy / Journal articles

To see the other types of publications on this topic, follow the link: Second-line therapy.

Journal articles on the topic 'Second-line therapy'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Second-line therapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Murphy, Richard A., Henry Sunpath, Carmen Castilla, et al. "Second-Line Antiretroviral Therapy." JAIDS Journal of Acquired Immune Deficiency Syndromes 61, no. 2 (2012): 158–63. http://dx.doi.org/10.1097/qai.0b013e3182615ad1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Calmy, Alexandra, Fernando Pascual, and Nathan Ford. "First-line and second-line antiretroviral therapy." Lancet 364, no. 9431 (2004): 329. http://dx.doi.org/10.1016/s0140-6736(04)16716-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Kulwichit, Wanla. "First-line and second-line antiretroviral therapy." Lancet 364, no. 9431 (2004): 329–30. http://dx.doi.org/10.1016/s0140-6736(04)16717-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Carr, Andrew. "First-line and second-line antiretroviral therapy." Lancet 364, no. 9431 (2004): 330. http://dx.doi.org/10.1016/s0140-6736(04)16718-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Weiss, Jared M., and Thomas E. Stinchcombe. "Second‐Line Therapy for Advanced NSCLC." Oncologist 18, no. 8 (2013): 947–53. http://dx.doi.org/10.1634/theoncologist.2013-0096.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Brandt, Kenneth D. "Second-line drug therapy for osteoarthritis." Clinical Medicine 1, no. 2 (2001): 110–12. http://dx.doi.org/10.7861/clinmedicine.1-2-110.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Martin, Mike G., Ramaswamy Govindan, and Daniel Morgensztern. "Second-line therapy for esophageal cancer." Expert Review of Anticancer Therapy 7, no. 6 (2007): 871–76. http://dx.doi.org/10.1586/14737140.7.6.871.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Hamers, Raph L. "Dolutegravir for second-line antiretroviral therapy." Lancet Infectious Diseases 19, no. 3 (2019): 218–19. http://dx.doi.org/10.1016/s1473-3099(19)30035-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Ahmed, Mili, Douma Rabiâa, Jarrar Emna, et al. "Second-Line Therapy in Multiple Sclerosis." Multiple Sclerosis and Related Disorders 37 (January 2020): 101586. http://dx.doi.org/10.1016/j.msard.2019.11.061.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Bachner, Mark, and Maria De Santis. "Second-line therapy in bladder cancer." Current Opinion in Urology 19, no. 5 (2009): 533–39. http://dx.doi.org/10.1097/mou.0b013e32832eb473.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Fleming, Gini F. "Second-Line Therapy for Endometrial Cancer." Obstetrical & Gynecological Survey 71, no. 7 (2016): 406–8. http://dx.doi.org/10.1097/01.ogx.0000484823.85897.c8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Breccia, Massimo. "Nilotinib: selective inhibitor as second-line therapy." Clinical Management Issues 4, no. 6S (2015): 3–5. http://dx.doi.org/10.7175/cmi.v4i6s.1096.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Simoneaux, Richard. "Second-Line Pembrolizumab Therapy for Urothelial Cancer." Oncology Times 39, no. 10 (2017): 16–18. http://dx.doi.org/10.1097/01.cot.0000520161.64831.c7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Buosi, R., A. Gatti, S. Carnio, A. Sponghini, C. Olympios, and O. Alabiso. "Second line therapy with cetuximab in NSCLC." Journal of Clinical Oncology 24, no. 18_suppl (2006): 17145. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.17145.

Full text

Abstract:

17145 Background: EGFR is overexpressed in different solid tumors and in 50–80% of NSCLC. The neoplastic growth and metastatic process is correlated with EGFR overexpression, so that it became the target of a new therapeutic approach. The monoclonal antibody (Mab) against the extracellular domain represent the most innovated method of EGFR inaction. Methods: From May to October 2005 10 patients (8 M and 2 F) of median age 62 years with NSCLC in stage IIIB-IV (7 adenocarcinomas and 3 squamocellulars) have been treated with the association of chemotherapy and Cetuximab. All patients presented a

APA, Harvard, Vancouver, ISO, and other styles

15

Gisbert, Javier P. "Review: Second-line rescue therapy ofHelicobacter pyloriinfection." Therapeutic Advances in Gastroenterology 2, no. 6 (2009): 331–56. http://dx.doi.org/10.1177/1756283x09347109.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Wood, Alastair J. J., Joseph M. Cash, and John H. Klippel. "Second-Line Drug Therapy for Rheumatoid Arthritis." New England Journal of Medicine 330, no. 19 (1994): 1368–75. http://dx.doi.org/10.1056/nejm199405123301908.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Sasako, Mitsuru. "Ramucirumab: second-line therapy for gastric cancer." Lancet Oncology 15, no. 11 (2014): 1182–84. http://dx.doi.org/10.1016/s1470-2045(14)70464-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Price, Timothy J. "Second-line therapy for metastatic colorectal cancer." Lancet Oncology 16, no. 5 (2015): 476–77. http://dx.doi.org/10.1016/s1470-2045(15)70169-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Ibañez, Patricio, E. Glasinovic, M. Gatica, Paula Vial, Eduardo Valdivieso, and Roque Saenz. "Inmunomodulation in Ulcerative Colitis. Second Line Therapy?" Gastrointestinal Endoscopy 65, no. 5 (2007): AB259. http://dx.doi.org/10.1016/j.gie.2007.03.606.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Chong, Geoff, and David Cunningham. "Second-line therapy for advanced colorectal cancer." Current Colorectal Cancer Reports 1, no. 1 (2005): 7–12. http://dx.doi.org/10.1007/s11888-005-0010-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Ritter, Timothy E., Chris Fourment, Samantha A. Kuten, Thomas C. Hardin, and Lucinda J. Van Anglen. "728 Second-Line Biologic Therapy After Vedolizumab." American Journal of Gastroenterology 114, no. 1 (2019): S429—S430. http://dx.doi.org/10.14309/01.ajg.0000592448.04563.6a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

WILLIAMS, H. JAMES. "COMBINATION SECOND-LINE THERAPY FOR RHEUMATOID ARTHRITIS." Rheumatology 33, no. 7 (1994): 603–4. http://dx.doi.org/10.1093/rheumatology/33.7.603.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Martin, M. G., A. Wang-Gillam, M. A. Waqar, et al. "Second-line systemic therapy for esophageal cancer." Journal of Clinical Oncology 26, no. 15_suppl (2008): 15623. http://dx.doi.org/10.1200/jco.2008.26.15_suppl.15623.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Starling, Naureen, and David Cunningham. "Second-line therapy for advanced colorectal carcinoma." Current Oncology Reports 7, no. 3 (2005): 173–80. http://dx.doi.org/10.1007/s11912-005-0070-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Savchenko, I. V., V. V. Breder, I. S. Stilidi, et al. "Second line drug therapy for biliary cancer." Meditsinskiy sovet = Medical Council, no. 22 (December 6, 2022): 136–47. http://dx.doi.org/10.21518/2079-701x-2022-16-22-136-147.

Full text

Abstract:

Biliary cancer is a group of tumors that develop from the epithelium of the intra- and extrahepatic bile ducts (cholangiocarcino-ma), as well as the gallbladder. For 10 years, chemotherapy based on a combination of gemcitabine and cisplatin has remained the standard of first-line therapy in patients with locally advanced or metastatic biliary cancer, resulting in a median overall survival of 11.7 months. With the progression of the disease on the first line, effective options did not previously exist. Attempts to use various chemotherapeutic regimens, both in monotherapy and in combination, ha

APA, Harvard, Vancouver, ISO, and other styles

26

Patrikar, Seema, Subramanian Shankar, Atul Kotwal, et al. "Predictors of first line antiretroviral therapy failure and burden of second line antiretroviral therapy." Medical Journal Armed Forces India 73, no. 1 (2017): 5–11. http://dx.doi.org/10.1016/j.mjafi.2016.09.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Dzhanyan, I. A., V. V. Breder, O. I. Borisova та K. K. Laktionov. "Рembrolizumab as second line therapy for hepatocellular patient". Meditsinskiy sovet = Medical Council, № 20 (12 грудня 2021): 150–54. http://dx.doi.org/10.21518/2079-701x-2021-20-150-154.

Full text

Abstract:

The optimal hepatocellular cancer (HCC) therapy remains a challenge. Due to checkpoint inhibitors patients with intolerance to the targeted therapy and or those with the impaired liver function can get an appropriate drug therapy. This clinical observation illustrates the long-term effect of pembrolizumab as the 2-line therapy in a patient diagnosed with. Sorafenib in standard doses as first line therapy led to severe toxicity and necessitated the withdrawal of therapy. Although subsequently the doses were reduced and concomitant medications used, sorafenib therapy was discontinued due to pron

APA, Harvard, Vancouver, ISO, and other styles

28

Lambert, Michele P. "Immunomodulatory Second-Line Therapies for Immune Thrombocytopenia." Hämostaseologie 39, no. 03 (2019): 266–71. http://dx.doi.org/10.1055/s-0039-1684032.

Full text

Abstract:

AbstractManagement of immune thrombocytopenia (ITP) is complex requiring communication between patients and caregivers to establish a mutual understanding of the impact of the patient's disease on quality of life, the current symptoms and risk of morbidity/mortality and the goals of therapy. The currently available second-line therapies for ITP provide potential for management of thrombocytopenia and bleeding symptoms with medical therapy or surgical intervention potentially offering long-term remission. All therapies are associated with potential side effects and necessary monitoring or modif

APA, Harvard, Vancouver, ISO, and other styles

29

Chaudhury, Bobby, and John Grainger. "UK second-line paediatric primary ITP therapy analysis." Archives of Disease in Childhood 106, no. 9 (2021): 929.1–931. http://dx.doi.org/10.1136/archdischild-2020-320646.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Raja, T. "Optimizing second-line therapy for chronic myeloid leukemia." Indian Journal of Cancer 49, no. 1 (2012): 46. http://dx.doi.org/10.4103/0019-509x.98918.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

&NA;. "Felbamate stays - but only as second-line therapy." Inpharma Weekly &NA;, no. 960 (1994): 21. http://dx.doi.org/10.2165/00128413-199409600-00044.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

&NA;. "Long-term second line therapy in rheumatoid arthritis." Inpharma Weekly &NA;, no. 971 (1995): 17. http://dx.doi.org/10.2165/00128413-199509710-00042.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

&NA;. "Prescribing second-line therapy for RA in France." Inpharma Weekly &NA;, no. 1327 (2002): 5. http://dx.doi.org/10.2165/00128413-200213270-00010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

&NA;. "Trimetrexate second-line therapy for AIDS-related PCP?" Inpharma Weekly &NA;, no. 1010 (1995): 5. http://dx.doi.org/10.2165/00128413-199510100-00010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Schmittel, Alexander. "Second-line therapy for small-cell lung cancer." Expert Review of Anticancer Therapy 11, no. 4 (2011): 631–37. http://dx.doi.org/10.1586/era.11.7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

&NA;. "Methotrexate - second-line therapy for superficial bladder cancer?" Inpharma Weekly &NA;, no. 892 (1993): 14. http://dx.doi.org/10.2165/00128413-199308920-00031.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

&NA;. "Felbamate stays ??? but only as second-line therapy." Reactions Weekly &NA;, no. 524 (1994): 2. http://dx.doi.org/10.2165/00128415-199405240-00002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Gerullis, Holger, Thomas Otto, and Thorsten H. Ecke. "Targeted agents in second-line bladder cancer therapy." Anti-Cancer Drugs 23, no. 10 (2012): 1003–15. http://dx.doi.org/10.1097/cad.0b013e3283582a33.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Currie, Graeme P., and Sudip Saha. "What About Add-On Second-Line Controller Therapy?" Chest 127, no. 3 (2005): 1077–78. http://dx.doi.org/10.1378/chest.127.3.1077.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Porter, D. R., I. McInnes, J. Hunter, and H. A. Capell. "Outcome of second line therapy in rheumatoid arthritis." Annals of the Rheumatic Diseases 53, no. 12 (1994): 812–15. http://dx.doi.org/10.1136/ard.53.12.812.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Pérez-Valero, Ignacio, and José R. Arribas. "Second-line antiretroviral therapy and the human factor." Lancet HIV 2, no. 2 (2015): e34-e35. http://dx.doi.org/10.1016/s2352-3018(15)00003-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Heath, Vicky. "Second-line therapy for adrenocortical carcinoma proves beneficial." Nature Reviews Endocrinology 6, no. 7 (2010): 355. http://dx.doi.org/10.1038/nrendo.2010.76.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Wachter, Kerri. "Vorinostat fails as second-line therapy for mesothelioma." Community Oncology 8, no. 10 (2011): 459. http://dx.doi.org/10.1016/s1548-5315(12)70150-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

BATES, BETSY. "Bleomycin as Second Line Therapy Clears Cancerous Lesions." Skin & Allergy News 39, no. 7 (2008): 30. http://dx.doi.org/10.1016/s0037-6337(08)70481-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

MECHCATIE, ELIZABETH. "Panel Backs Romidepsin as Second-Line CTCL Therapy." Skin & Allergy News 40, no. 10 (2009): 8. http://dx.doi.org/10.1016/s0037-6337(09)70478-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Bex, Axel. "Prognostic accuracy in second-line renal cancer therapy." Lancet Oncology 16, no. 3 (2015): 240–41. http://dx.doi.org/10.1016/s1470-2045(15)70009-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Gourd, Elizabeth. "Promising new second-line therapy for Hodgkin lymphoma." Lancet Oncology 20, no. 2 (2019): e76. http://dx.doi.org/10.1016/s1470-2045(19)30016-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Timcheva, C. "Second-line targeted therapy of gastrointestinal stromal tumours." memo - Magazine of European Medical Oncology 3, no. 2 (2010): 61–64. http://dx.doi.org/10.1007/s12254-010-0196-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Bird, H. A. "Long-term second-line therapy in rheumatoid arthritis." Clinical Rheumatology 4, no. 2 (1985): 121–23. http://dx.doi.org/10.1007/bf02032281.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Zustovich, Fable, Giuseppe Lombardi, Ornella Nicoletto, and Davide Pastorelli. "Second-line therapy for refractory renal-cell carcinoma." Critical Reviews in Oncology/Hematology 83, no. 1 (2012): 112–22. http://dx.doi.org/10.1016/j.critrevonc.2011.08.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!